Drug Use Investigation of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Trial Profile

Drug Use Investigation of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 May 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms JPMS-CTEPH
  • Sponsors Bayer
  • Most Recent Events

    • 13 Mar 2017 Planned End Date changed from 1 Jan 2024 to 16 Jan 2024.
    • 13 Mar 2017 Planned primary completion date changed from 1 Sep 2022 to 30 Sep 2022.
    • 18 Dec 2015 Planned primary completion date changed from 1 Mar 2023 to 1 Sep 2022 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top